Loading
Yanuki
KEYWORD TOPIC
Eli Lilly Stock: Setbacks and Alternative Investments in 2026 | Eli Lilly's Tirzepatide Becomes World's Best-Selling Drug | Trump's Tariffs and Healthcare Sector Challenges | Eli Lilly Stock: Setbacks and Alternative Investments in 2026 | Eli Lilly's Tirzepatide Becomes World's Best-Selling Drug | Trump's Tariffs and Healthcare Sector Challenges

Finance / Stocks

Eli Lilly Stock: Setbacks and Alternative Investments in 2026

Eli Lilly (LLY) faces a setback in the weight loss drug market as its oral GLP-1 candidate, orforglipron, experiences FDA review delays. This article examines the implications and explores alternative investment opportunities in the pharmac...

Should You Dump Eli Lilly's Shares After This Setback?
Eli Lilly Stock: Setbacks and Alternative Investments in 2026 Image via The Motley Fool
TOPIC eli lilly stock

Finance / Stocks

Eli Lilly's Tirzepatide Becomes World's Best-Selling Drug

Eli Lilly's tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, has become the world's top-selling drug, surpassing Merck's Keytruda. This reflects the increasing demand for GLP-1 drugs and Eli Lilly's strong market pos...

This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?

Finance / Healthcare

Trump's Tariffs and Healthcare Sector Challenges

The healthcare sector is facing a confluence of challenges, including potential tariffs on pharmaceuticals, increasing regulatory scrutiny, and evolving financial strategies. These factors are creating uncertainty and volatility in the mark...

President Trump Just Announced Terrible News for Eli Lilly Investors